Targeting CDK 2 overcomes melanoma resistance against BRAF and Hsp90 inhibitors
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
Targeting CDK 2 overcomes melanoma resistance against BRAF and Hsp90 inhibitors ; volume:14 ; number:3 ; year:2018 ; extent:16
Molecular systems biology ; 14, Heft 3 (2018) (gesamt 16)
- Urheber
-
Azimi, Alireza
Caramuta, Stefano
Seashore‐Ludlow, Brinton
Boström, Johan
Robinson, Jonathan L.
Edfors, Fredrik
Tuominen, Rainer
Kemper, Kristel
Krijgsman, Oscar
Peeper, Daniel S.
Nielsen, Jens
Hansson, Johan
Egyhazi Brage, Suzanne
Altun, Mikael
Uhlen, Mathias
Maddalo, Gianluca
- DOI
-
10.15252/msb.20177858
- URN
-
urn:nbn:de:101:1-2022082305530918157910
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:21 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Azimi, Alireza
- Caramuta, Stefano
- Seashore‐Ludlow, Brinton
- Boström, Johan
- Robinson, Jonathan L.
- Edfors, Fredrik
- Tuominen, Rainer
- Kemper, Kristel
- Krijgsman, Oscar
- Peeper, Daniel S.
- Nielsen, Jens
- Hansson, Johan
- Egyhazi Brage, Suzanne
- Altun, Mikael
- Uhlen, Mathias
- Maddalo, Gianluca
Ähnliche Objekte (12)
Inhibitors of HSP90 in melanoma
Co-targeting HSP90 alpha and CDK7 overcomes resistance against HSP90 inhibitors in BCR-ABL1+ leukemia cells
Dual EGFR and BRAF blockade overcomes resistance to vemurafenib in BRAF mutated thyroid carcinoma cells
CDK
Targeting Discoidin Domain Receptors DDR1 and DDR2 overcomes matrix‐mediated tumor cell adaptation and tolerance to BRAF‐targeted therapy in melanoma
Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated
Response to BRAF/MEK Inhibition in A598_T599insV BRAF Mutated Melanoma
Optimizing the treatment of BRAF mutant melanoma
Novel combination therapies for BRAF-mutant melanoma
Convent Deutscher Kooperationsverbände (CDK): CDK .- Bundeszuschüsse
CDK-Conventsprotokolle
CDA / CDK
Inhibitors of HSP90 in melanoma
Co-targeting HSP90 alpha and CDK7 overcomes resistance against HSP90 inhibitors in BCR-ABL1+ leukemia cells
Dual EGFR and BRAF blockade overcomes resistance to vemurafenib in BRAF mutated thyroid carcinoma cells
CDK
Targeting Discoidin Domain Receptors DDR1 and DDR2 overcomes matrix‐mediated tumor cell adaptation and tolerance to BRAF‐targeted therapy in melanoma
Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated
Response to BRAF/MEK Inhibition in A598_T599insV BRAF Mutated Melanoma
Optimizing the treatment of BRAF mutant melanoma
Novel combination therapies for BRAF-mutant melanoma
Convent Deutscher Kooperationsverbände (CDK): CDK .- Bundeszuschüsse
CDK-Conventsprotokolle
CDA / CDK
Inhibitors of HSP90 in melanoma
Co-targeting HSP90 alpha and CDK7 overcomes resistance against HSP90 inhibitors in BCR-ABL1+ leukemia cells
Dual EGFR and BRAF blockade overcomes resistance to vemurafenib in BRAF mutated thyroid carcinoma cells
CDK
Targeting Discoidin Domain Receptors DDR1 and DDR2 overcomes matrix‐mediated tumor cell adaptation and tolerance to BRAF‐targeted therapy in melanoma
Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated
Response to BRAF/MEK Inhibition in A598_T599insV BRAF Mutated Melanoma
Optimizing the treatment of BRAF mutant melanoma
Novel combination therapies for BRAF-mutant melanoma
Convent Deutscher Kooperationsverbände (CDK): CDK .- Bundeszuschüsse
CDK-Conventsprotokolle